Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 24, 2016
Pharmacy Choice - News - Generic Drugs - September 24, 2016

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 66     Next >>     Go To Page:

9/24/16 - 80 new pharmaceutical jobs for north Dublin [Seven Days (United Arab Emirates)]
Pharmaceutical group Alter Pharma has announced plans to add 80 new jobs in Ireland after inaugurating a new headquarters for its worldwide operations in Balbriggan, Co Dublin today. Founded in 2010, Alter Pharma has five companies based in Ireland Generic Specialty Pharma, Generic Pharma International, Steac Pharmaceuticals, Beta Active PI Pharma
9/24/16 - Beshear joins lawsuit against maker of opioid treatment drug [Lexington Herald-Leader]
Sept. 24 Attorney General Andy Beshear has joined a multistate lawsuit against the makers of Suboxone, an opioid treatment drug, that alleges the pharmaceutical company blocked cheaper generic competitors and gouged customers with artificially high prices. The lawsuit alleges Reckitt Benckiser Pharmaceuticals, which is now known as Indivior, cons
9/24/16 - FDA approves Amjevita, a biosimilar to Humira [Palestine Chronicle, The]
The U.S. Food and Drug Administration today approved Amjevita as a biosimilar to Humira for multiple inflammatory diseases. This is the fourth FDA- approved biosimilar. The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions, said Janet Woodcock, M.D., direc
9/24/16 - Maine joins suit against anti-addiction drug maker, months after company got a business boon [Bangor Daily News, Maine]
Sept. 23 Maine and 35 other states on Friday sued the maker of the opioid addiction treatment medication Suboxone. The antitrust suit alleges that Reckitt Benckiser Pharmaceuticals, now known as Indivior, conspired with another company, MonoSol Rx, to block generic competitors for Suboxone. Maine Attorney General Janet Mills did not mince words i
9/24/16 - One step closer to drug price controls [Seven Days (United Arab Emirates)]
Since Congress likes nothing more than to jump on the bandwagon of public outrage, the House of Representatives has entered the conversation of outrageous prescription drug pricing. The recently introduced Fair Accountability and Innovative Research Drug Pricing Act of 2016, otherwise known as the FAIR Drug Pricing Act, seeks to force drug-makers t
9/23/16 - 2024 Peripheral Artery Disease - US Drug Forecast, Market Share, Trend, Growth, Analysis and Research Report
Researchmoz added Most up-to-date research on "Peripheral Artery Disease- US Drug Forecast and Market Analysis to 2024" to its huge collection of research reports.Albany, NY 09/23/2016 In the 2014 base year, the global PAD market was worth approximately $543.4 m, including both branded and generic drugs. By 2024, GlobalData expects that the g
9/23/16 - 35 US states sue British drugmaker over marketing of opioid
SAN FRANCISCO Thirty-five states and the District of Columbia filed an antitrust lawsuit Thursday alleging that British drugmaker Indivior tried to keep cheaper, generic versions of Suboxone off the market, California's attorney general announced.
9/23/16 - Alter Pharma creating new jobs at its global headquarters in Dublin [Big News Network (United Arab Emirates)]
The company has five firms in Ireland already, including Generic Specialty Pharma Ltd, Generic Pharma International Ltd, Steac Pharmaceuticals Ltd, Beta Active PI Pharma Ltd and Novalus Healthcare Ltd and is investing an additional 5 million euros for a new facility in the country. The company's expansion to add another facility is supported by IDA
9/23/16 - Azp 241-110 / 16. Purchase With The Delivery Of Cancer Drugs, Generic Drugs, Infusion Solutions For Hospital Pharmacies Holy Cross Cancer Center In Kielce. [TendersInfo (India)]
Contract notice: Azp 241-110/ 16. purchase with the delivery of cancer drugs, generic drugs, infusion solutions for hospital pharmacies holy cross cancer center in kielce. The contract is for the purchase with the delivery of cancer drugs, generic drugs, infusion solutions for Hospital Pharmacies Holy Cross Cancer Center in Kielce according to Pack
9/23/16 - Chairman Moran Conducts Hearing on FDA's Role in Generic Drug Marketplace
WASHINGTON- U.S. Senator Jerry Moran, Chairman of the Senate Agriculture Appropriations Committee, presided over a hearing this week to examine the FDA's Role in the generic drug marketplace. "We have seen the impact that escalating costs of name-brand drugs has on Americans and their families," Sen. Moran said. Over the past three years, the FDA
9/23/16 - FDA Approves Amgen's AMJEVITA? (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases
Amgen today announced that the U.S. Food and Drug Administration has approved AMJEVITA? across all eligible indications of the reference product, Humira . AMJEVITA is Amgen's first biosimilar to receive regulatory approval. In addition, AMJEVITA holds the potential to offer patients with chronic inflammatory diseases an additional treatment o
9/23/16 - FDA approves Amjevita, a biosimilar to Humira
The U.S. Food and Drug Administration today approved Amjevita as a biosimilar to Humira for multiple inflammatory diseases. "This is the fourth FDA- approved biosimilar. The biosimilar pathway is still a new frontier and one that we expect will enhance access to treatment for patients with serious medical conditions, "said Janet Woodcock, M.D., di
9/23/16 - Lori Swanson sues to expand access to opioid addiction treatment drug [Star Tribune (Minneapolis)]
Sept. 23 Seeking to expand access to one of the few drug treatments for opioid addiction, Minnesota Attorney General Lori Swanson took several steps Thursday to increase production of the drug, reduce prices and remove insurance barriers. Joining attorneys general from 34 other states, Swanson sued Indivior, a Virginia- based drug manufacturer, t
9/23/16 - Maryland among 36 states suing makers of heroin addiction treatment drug Suboxone for antitrust violations [The Baltimore Sun]
Sept. 23 Maryland and 35 other states filed an antitrust lawsuit Thursday against the makers of the opioid addiction treatment drug Suboxone. The lawsuit, filed in U.S. District Court for the Eastern Division of Pennsylvania, alleges that Reckitt Benckiser, now known as Indivior, and MonoSol Rx conspired to block generic competitors for Suboxone
9/23/16 - Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry; Availability
SUMMARY: The Food and Drug Administration is announcing the availability of a guidance for industry entitled "Self-Identification of Generic Drug Facilities, Sites, and Organizations." GDUFA, designed to speed the delivery of safe and effective generic drugs to the public and reduce costs to industry, requires that generic drug facilities, sites, a
9/23/16 - State joins 'product hopping' lawsuit [The Day, New London, Conn.]
Sept. 23 Attorney General George Jepsen announced Friday that the state has joined in a federal lawsuit charging two pharmaceutical firms with "product hopping" that illegally blocked generic competition to the opioid-addiction drug Suboxone. Connecticut is one of 35 states and the District of Columbia to have joined the lawsuit filed Thursday.
9/23/16 - UK IBD audit highlights potential huge cost savings of using new biosimilar medicines
This year's national clinical audit of biological therapies for IBD, published by the Royal College of Physicians on behalf of the IBD audit programme today, is the latest report to assess the use of these therapies in treating the condition. These drugs have been available in the UK from February 2015 and are designed to have active properties sim
9/23/16 - ViiV Healthcare welcomes the FDA's Tentative Approval of the first generic dolutegravir from Aurobindo Pharma
Release date- 22092016- ViiV Healthcare welcomes today's decision by the US Food and Drug Administration to grant Aurobindo Pharma Tentative Approval for the first generic version of dolutegravir 50 mg for the treatment of HIV in the developing world. 'We think that this Tentative Approval of the first generic dolutegravir from Aurobindo will impro
9/22/16 - Allergan and Adamas Announce U.S. Availability of New Dosage Strengths for NAMZARIC (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
DUBLIN and EMERYVILLE, Calif., Sept. 22, 2016/ PRNewswire/ Allergan plc, a leading global pharmaceutical company, and Adamas Pharmaceuticals, Inc. announced today that all four dosage strengths of NAMZARIC extended-release capsules that allow patients on donepezil 10 mg to start directly on NAMZARIC are now available by prescription in pharmac
9/22/16 - Controversy Pullback Offers Good Entry Point For Mylan
Argus' Jacob Kilstein believes generic drug companies would "continue to benefit from the increased focus on cost-effective healthcare." Kilstein maintains a Buy rating and a $55 price target on Mylan NV. The company also offered $300 coupons to some of the users, while on August 29, Mylan announced it would launch a generic EpiPen in the near futu
9/22/16 - Cooper Supports Bill to Prevent Excessive Drug Price Increases
Jim Cooper and other members of the Blue Dog Coalition this week endorsed a bill that could prevent dramatic drug price hikes seen recently with the EpiPen and other medicines. The bill would help streamline the FDA approval process on generic drugs. Turing Pharmaceuticals CEO Martin Shkreli raised the price of a life-saving drug by more than 5,000
9/22/16 - Cotton Introduces the Safely Advancing Valuable and Inexpensive New Generic Solutions Act
It would also require the FDA to make a final approval decision within 150 days of receiving the priority review applications. "Regrettably, the current FDA backlog of new generic drug applications awaiting approval is only making this problem worse. Expediting the approval process for both the first and the second generic and requiring the FDA to
9/22/16 - Global Hormone Replacement Therapy (HRT) Industry
The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. The report profiles 40 companies including many key and niche players such as- Abbott Laboratories AbbVie, Inc. Allergan plc Bayer Pharma AG Hisamitsu Pharmaceutical Co., Inc. Read the full report:...
9/22/16 - Impax Launches Generic Version of Metadate CD (Methylphenidate Hydrochloride Extended-Release Capsules)
Impax Laboratories, Inc. today announced the launch of a generic version of Metadate CD , 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg. Impax is focused on further enhancing its portfolio of 73 solid oral dose and alternative dosage form generic products available. About Impax Laboratories, Inc. Impax Laboratories, Inc. is a specialty pharmaceu
9/22/16 - Intellipharmaceutics Responds to Recent Trading Activity
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products and...
Articles(s): 1 - 25 of 66     Next >>     Go To Page:

© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement